Invitris
PrivateLast Round
Grant
Feb 17, 2025
Total Funding Raised
$3.33M
Company Overview
Invitris is a German biotechnology company that develops drugs to treat antibiotic-resistant infections. The company was founded in 2019 as a spin-off from a Technical University of Munich (TUM) research team. Invitris utilizes a proprietary cell-free protein expression technology platform, called Phactory™, to develop and manufacture next-generation proteins, including bacteriophages, antibodies, and enzymes. The company's mission is to combat antimicrobial resistance (AMR) by creating personalized, on-demand therapeutic proteins. Invitris partners with biopharmaceutical companies to co-develop and manufacture these novel protein structures for various fields, including oncology, neurodegenerative diseases, and agriculture. The company has received funding from entities such as Y Combinator and the European Innovation Council (EIC) Accelerator to scale its platform and advance its treatments toward clinical translation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Pharma Supply Chain, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Invitris Comps
Public and private peers based on sector, stage, and business model.
Invitris Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 17, 2025 | ||||
| Grant | May 15, 2023 | ||||
| Seed | Mar 10, 2023 |
Invitris Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council | Grant |
| INCATE | Grant |
| Y Combinator | Seed |
| another.vc | Seed |
| 10x Founders | Seed |
| Mergus Ventures | Seed |
Invitris Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Invitris's valuation, stock price, and market status.
